Integrated ECG Leader ACS Diagnostics has developed and patented an all-in-one ECG monitoring device (CORE12) that combines 4 cardiac modalities in a single phone unit with integrated cellular transmission, offering a strong differentiator for cardiology practices and telemedicine workflows.

Expansion Pipeline The upcoming CORE12 patch miniaturization signals ongoing product evolution and potential upsell opportunities to customers adopting the CORE12, enabling broader patient wearability programs and new reimbursement-ready solutions.

Telemedicine Focus A strategic emphasis on telemedicine and mobile telemetry enables remote monitoring capabilities, opening conversations with clinics and hospitals expanding virtual care, remote patient monitoring programs, and IDTF partnerships.

Growth Readiness With a revenue range of one to ten million and a current funding round, ACS Diagnostics presents an attractive target for strategic partnerships, private equity interest, or channel partners seeking innovative neurology/cardiology monitoring platforms.

Market Positioning As a smaller, specialized medical equipment manufacturer serving cardiologists, internists, and general practitioners, there are clear cross-sell opportunities to expand within existing accounts and adjacent specialties that rely on comprehensive ECG monitoring and patient-centric data.